The global market for peripheral vascular stents, which was valued at $1.1 billion in 2013, has entered into a dynamic phase which will be characterized by the rising prevalence of peripheral artery disease (PAD), growing availability in key regional markets, and the adoption of potentially competitive products, such as drug-coated balloons (DCBs). In the U.S., where DCBs became commercially available in October 2014, the use of stents will continue to be driven by the availability of products that enable treatment for different types of lesions and have indications specific to the target anatomy-e.g., the carotid, femoral, popliteal, iliac, and renal arteries. This should contribute to growing use in patients at high risk for problems following surgical intervention as well as those with applicable lesion profiles. In Europe, where cost-containment efforts are expected to generate price erosion, demographic factors and the use of stents as part of a multi-modal treatment strategy will fuel revenue gains. And in countries in the Asia-Pacific region and the rest of the world, growth will be driven by greater access to care and rising access in underpenetrated markets.
Critical Issues Covered in this Report:
• The competitive landscape for these devices in the U.S. and international markets;
• Quantitative factors including units, pricing, and product sales; and
• Procedure volumes as well as other key infrastructure and market metrics.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
